Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/cup.12800 http://scihub22266oqcxt.onion/10.1111/cup.12800 C5507594!5507594!27531597     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27531597.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Cutan+Pathol 2016 ; 43 (11): 989-93 Nephropedia Template TP {{tp|p=27531597|t=2016. Histopathologic Spectrum of Hypersensitivity Reactions Associated with anti-CD52 Therapy (Alemtuzumab) |pdf=|usr=}}{{27531597}} gab.com Text Histopathologic Spectrum of Hypersensitivity Reactions Associated with anti-CD52 Therapy (Alemtuzumab) JO: J Cutan Pathol http://www.kidney.de/pget.php?&tw=1&pmid=27531597 #FOAvip Background: Alemtuzumab is a humanized monoclonal antibody directed against CD52, a cell surface antigen on B and T lymphocytes, and used to treat B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma. Skin rash is a common adverse reaction following treatment with alemtuzumab. However, the clinicopathologic features and immunologic basis for the reaction have not been previously reported. Methods: Our hospital's electronic pathology database was searched for cases with documentation of ?alemtuzumab? or ?anti-CD52? in the clinical history provided by either the ordering physician or the pathologist. Clinical and histopathologic review of the cases was performed. Results: Five patients with CTCL or CLL were treated with alemtuzumab, and developed pruritic, erythematous papules and plaques. Histopathology of the skin lesions revealed subacute spongiotic dermatitis with multifocal parakeratosis, endothelial activation and perivascular lymphocytic infiltrate. Eosinophils were not a prominent feature. Conclusions: We describe the clinicopathologic features of a novel hypersensitivity reaction to alemtuzumb, and hypothesize it may be due to an immunologic response precipitated by the persistence of resident memory T-cells (TRM) in the skin. Our findings raise awareness for a novel reaction pattern and guide the histopathologic interpretation of lesions which may clinically mimic residual or recurrent cutaneous lymphoproliferative disorders. Twit Text FOAVip Histopathologic Spectrum of Hypersensitivity Reactions Associated with anti-CD52 Therapy (Alemtuzumab) ????J Cutan Pathol http://www.kidney.de/pget.php?&tw=1&pmid=27531597 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27531597 #FOAvip English Wikipedia <ref>{{Cite pmid|27531597}}</ref> Histopathologic Spectrum of Hypersensitivity Reactions Associated with anti-CD52 Therapy (Alemtuzumab) #MMPMID27531597 Clark SL; Tse JY; Fisher DE; LeBeouf NR; Murphy GF; Kupper TS; Clark RA; Lian CG J Cutan Pathol 2016[Nov]; 43 (11): 989-93 PMID27531597show ga Background: Alemtuzumab is a humanized monoclonal antibody directed against CD52, a cell surface antigen on B and T lymphocytes, and used to treat B-cell chronic lymphocytic leukemia and cutaneous T-cell lymphoma. Skin rash is a common adverse reaction following treatment with alemtuzumab. However, the clinicopathologic features and immunologic basis for the reaction have not been previously reported. Methods: Our hospital's electronic pathology database was searched for cases with documentation of ?alemtuzumab? or ?anti-CD52? in the clinical history provided by either the ordering physician or the pathologist. Clinical and histopathologic review of the cases was performed. Results: Five patients with CTCL or CLL were treated with alemtuzumab, and developed pruritic, erythematous papules and plaques. Histopathology of the skin lesions revealed subacute spongiotic dermatitis with multifocal parakeratosis, endothelial activation and perivascular lymphocytic infiltrate. Eosinophils were not a prominent feature. Conclusions: We describe the clinicopathologic features of a novel hypersensitivity reaction to alemtuzumb, and hypothesize it may be due to an immunologic response precipitated by the persistence of resident memory T-cells (TRM) in the skin. Our findings raise awareness for a novel reaction pattern and guide the histopathologic interpretation of lesions which may clinically mimic residual or recurrent cutaneous lymphoproliferative disorders. äHistopathologic Spectrum of Hypersensitivity Reactions Associated with(epmc).pdf DeepDyve Pubget Overpricing